Post by
zalmonella on Jul 02, 2021 12:49pm
What opportunity is there?
Hmmm.... I see a note to myself from January after I sold to check back in summertime to buy more below $3. Well, it's below $3.
But why? What catalysts are there? So dosing is occurring - will there be any news before 2022? There's a lotta turnover recently, but no new ideas. I'm a big fan of adjuvants - I think that's where the real improvements are in drug therapies, so there should be some good news rolling out on a regular basis. But that doesnt' seem to be true at all for IMV. And with only about 9 months of cash left, there's no opportunity for a refinancing at a decent price, which means more dilution and even less return.
I think they've lost their way.
Comment by
gardy on Jul 02, 2021 1:37pm
They're just looking after their salaries. Gardy